



Age/Gender : 40 Y 7 M 11 D/M
UHID/MR No : CINR.0000157409
Visit ID : CINROPV206921

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9855043666 Collected : 04/Oct/2023 09:42AM
Received : 04/Oct/2023 02:38PM
Reported : 04/Oct/2023 06:26PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HAEMOGLOBIN	15.6	g/dL	13-17	Spectrophotometer
PCV	47.20	%	40-50	Electronic pulse & Calculation
RBC COUNT	5.23	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	90.3	fL	83-101	Calculated
MCH	29.8	pg	27-32	Calculated
MCHC	33.1	g/dL	31.5-34.5	Calculated
R.D.W	14.9	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,730	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (D	LC)			
NEUTROPHILS	52.7	%	40-80	Electrical Impedance
LYMPHOCYTES	36.2	%	20-40	Electrical Impedance
EOSINOPHILS	3.4	%	1-6	Electrical Impedance
MONOCYTES	7.4	%	2-10	Electrical Impedance
BASOPHILS	0.3	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	3019.71	Cells/cu.mm	2000-7000	Electrical Impedance
LYMPHOCYTES	2074.26	Cells/cu.mm	1000-3000	Electrical Impedance
EOSINOPHILS	194.82	Cells/cu.mm	20-500	Electrical Impedance
MONOCYTES	424.02	Cells/cu.mm	200-1000	Electrical Impedance
BASOPHILS	17.19	Cells/cu.mm	0-100	Electrical Impedance
PLATELET COUNT	150000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	12	mm at the end of 1 hour	0-15	Modified Westegrer method

RBCs: are normocytic normochromic

WBCs: are normal in total number with normal distribution and morphology.

PLATELETS: appear adequate in number.

HEMOPARASITES: negative

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE

Page 1 of 13







: Mr.DEVASHISH KUMAR SINGH

Age/Gender UHID/MR No : 40 Y 7 M 11 D/M : CINR.0000157409

Visit ID

: CINROPV206921

Ref Doctor Emp/Auth/TPA ID

: Dr.SELF : 9855043666 Collected

: 04/Oct/2023 09:42AM

Received

: 04/Oct/2023 02:38PM : 04/Oct/2023 06:26PM

Reported Status

: Final Report

Sponsor Name


: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - F	FULL BODY ANNUAL	PLUS MALE - TMT -	- PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

Page 2 of 13







: Mr.DEVASHISH KUMAR SINGH

Age/Gender UHID/MR No : 40 Y 7 M 11 D/M : CINR.0000157409

Visit ID

: CINROPV206921

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 9855043666 Collected

: 04/Oct/2023 09:42AM

Received

: 04/Oct/2023 02:38PM : 04/Oct/2023 07:07PM

Reported Status

: Final Report

Sponsor Name


: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL	- FULL BODY ANNU	JAL PLUS MALI	E - TMT - PAN INDIA - F	Y2324
Test Name	Result	Unit	Bio. Ref. Range	Method

BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA				
BLOOD GROUP TYPE	0	Microplate Hemagglutination		
Rh TYPE	Positive	Microplate Hemagglutination		

Page 3 of 13









: Mr.DEVASHISH KUMAR SINGH

Age/Gender UHID/MR No : 40 Y 7 M 11 D/M : CINR.0000157409

Visit ID

: CINROPV206921

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 9855043666 Collected

: 04/Oct/2023 09:42AM

Received

: 04/Oct/2023 02:56PM

Reported Status : 04/Oct/2023 03:21PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL	- FULL BODY ANNU	JAL PLUS MALI	E - TMT - PAN INDIA - F	Y2324	
Test Name	Result	Unit	Bio. Ref. Range	Method	

GLUCOSE, FASTING , NAF PLASMA	94	mg/dL	70-100	HEXOKINASE
-------------------------------	----	-------	--------	------------

Comment:

As per American Diabetes Guidelines, 2023

15 per rimerieum Diametes Garacimes, 2020			
Fasting Glucose Values in mg/dL	Interpretation		
70-100 mg/dL	Normal		
100-125 mg/dL	Prediabetes		
≥126 mg/dL	Diabetes		
<70 mg/dL	Hypoglycemia		

Note:

1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.

2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 4 of 13









Age/Gender : 40 Y 7 M 11 D/M UHID/MR No : CINR.0000157409 Visit ID : CINROPV206921

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9855043666 Collected : 04/Oct/2023 09:42AM Received : 04/Oct/2023 02:33PM

Reported : 04/Oct/2023 05:15PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DED	DTMENT	OF DIO	CHEMISTRY
	7 K I MILIA I	UF BIU	CHEIVIISIRT

ARCOFEMI - MEDIWHEEL	- FULL BODY ANNU	JAL PLUS MALE	E - TMT - PAN INDIA - F	Y2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GLUCOSE, POST PRANDIAL (PP), 2	170	mg/dL	70-140	HEXOKINASE
HOURS, SODIUM FLUORIDE PLASMA (2				
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.7	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG), WHOLE BLOOD EDTA	117	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF >25%
 - B: Homozygous Hemoglobinopathy.

Page 5 of 13







: Mr.DEVASHISH KUMAR SINGH

Age/Gender UHID/MR No : 40 Y 7 M 11 D/M : CINR.0000157409

Visit ID

: CINROPV206921

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 9855043666 Collected

: 04/Oct/2023 09:42AM

Received Reported : 04/Oct/2023 02:33PM : 04/Oct/2023 05:15PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

Test Name Result Unit Bio. Ref. Range Method

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 13









Age/Gender : 40 Y 7 M 11 D/M
UHID/MR No : CINR.0000157409
Visit ID : CINROPV206921

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9855043666 Collected : 04/Oct/2023 09:42AM
Received : 04/Oct/2023 02:30PM
Reported : 04/Oct/2023 05:09PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

	DEI ARTIMENT OF	DICCITLINICITY	·	
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324				
Test Name	Result	Unit	Bio. Ref. Range	Method

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	178	mg/dL	<200	CHO-POD
TRIGLYCERIDES	137	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	48	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	130	mg/dL	<130	Calculated
LDL CHOLESTEROL	102.1	mg/dL	<100	Calculated
VLDL CHOLESTEROL	27.4	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.70		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 7 of 13

SIN No:SE04501120





Age/Gender : 40 Y 7 M 11 D/M
UHID/MR No : CINR.0000157409
Visit ID : CINROPV206921

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9855043666 Collected : 04/Oct/2023 09:42AM
Received : 04/Oct/2023 02:30PM
Reported : 04/Oct/2023 05:09PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.64	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.12	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.52	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	67	U/L	<50	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	45.0	U/L	<50	IFCC
ALKALINE PHOSPHATASE	140.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.32	g/dL	6.6-8.3	Biuret
ALBUMIN	4.43	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	2.89	g/dL	2.0-3.5	Calculated
A/G RATIO	1.53		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- · Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

${\bf 3. \ Synthetic \ function \ impairment:}$

- · Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 8 of 13

SIN No:SE04501120





: Mr.DEVASHISH KUMAR SINGH

Age/Gender UHID/MR No : 40 Y 7 M 11 D/M : CINR.0000157409

Visit ID

: CINROPV206921

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 9855043666 Collected

: 04/Oct/2023 09:42AM

Received

: 04/Oct/2023 02:30PM

Reported Status : 04/Oct/2023 05:09PM : Final Report

Sponsor Name


: ARCOFEMI HEALTHCARE LIMITED

ARCOFEMI - MEDIWHEEL	- FULL BODY ANNU	JAL PLUS MALI	E - TMT - PAN INDIA - F	Y2324	
Test Name	Result	Unit	Bio. Ref. Range	Method	

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM						
CREATININE	0.70	mg/dL	0.72 – 1.18	JAFFE METHOD		
UREA	13.90	mg/dL	17-43	GLDH, Kinetic Assay		
BLOOD UREA NITROGEN	6.5	mg/dL	8.0 - 23.0	Calculated		
URIC ACID	4.52	mg/dL	3.5–7.2	Uricase PAP		
CALCIUM	8.90	mg/dL	8.8-10.6	Arsenazo III		
PHOSPHORUS, INORGANIC	3.38	mg/dL	2.5-4.5	Phosphomolybdate Complex		
SODIUM	139	mmol/L	136–146	ISE (Indirect)		
POTASSIUM	4.2	mmol/L	3.5–5.1	ISE (Indirect)		
CHLORIDE	105	mmol/L	101–109	ISE (Indirect)		

Page 9 of 13









: Mr.DEVASHISH KUMAR SINGH

Age/Gender UHID/MR No : 40 Y 7 M 11 D/M : CINR.0000157409

Visit ID

: CINROPV206921

Ref Doctor Emp/Auth/TPA ID

: Dr.SELF : 9855043666 Collected

: 04/Oct/2023 09:42AM

Received

: 04/Oct/2023 02:30PM

Reported Status : 04/Oct/2023 05:09PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

ARCOFEMI - MEDIWHEEL	ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method		

GAMMA GLUTAMYL TRANSPEPTIDASE	42.00	U/L	<55	IFCC	
(GGT) , SERUM					

Page 10 of 13







Age/Gender : 40 Y 7 M 11 D/M
UHID/MR No : CINR.0000157409
Visit ID : CINROPV206921

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9855043666 Collected : 04/Oct/2023 09:42AM

Received : 04/Oct/2023 02:30PM Reported : 04/Oct/2023 04:47PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL	- FULL BODY ANNU	JAL PLUS MALI	E - TMT - PAN INDIA - F	Y2324
Test Name	Result	Unit	Bio. Ref. Range	Method

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM				
TRI-IODOTHYRONINE (T3, TOTAL)	1.41	ng/mL	0.64-1.52	CMIA
THYROXINE (T4, TOTAL)	8.97	μg/dL	4.87-11.72	CMIA
THYROID STIMULATING HORMONE (TSH)	7.290	μIU/mL	0.35-4.94	CMIA

Comment:

ikar aregnani iemaies	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 11 of 13



SIN No:SPL23141401





Age/Gender : 40 Y 7 M 11 D/M
UHID/MR No : CINR.0000157409
Visit ID : CINROPV206921

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9855043666 Collected : 04/Oct/2023 09:42AM
Received : 04/Oct/2023 01:26PM
Reported : 04/Oct/2023 03:24PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY					
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					

COMPLETE URINE EXAMINATION (C	UE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	5.5		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.020		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE	F.	NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	OUNT AND MICROSCOPY			
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 12 of 13



SIN No:UR2195824





: Mr.DEVASHISH KUMAR SINGH

Age/Gender UHID/MR No : 40 Y 7 M 11 D/M : CINR.0000157409

Visit ID

: CINROPV206921

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 9855043666 Collected

: 04/Oct/2023 09:42AM

Received

: 04/Oct/2023 01:26PM

Reported

: 04/Oct/2023 03:36PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT	OF CLIMI	CAL DAT	LOI OCV
DEPARTMENT	OF GLINI	CALPAI	HULUGY

ARCOFEMI - MEDIWHEEL	- FULL BODY ANNU	JAL PLUS MALI	E - TMT - PAN INDIA - F	Y2324
Test Name	Result	Unit	Bio. Ref. Range	Method

URINE GLUCOSE(POST PRANDIAL)	NEGATIVE	NEGATIVE	Dipstick

URINE GLUCOSE(FASTING) NEGATIVE NEGATIVE Dipstick

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

DR.SHIVARAJA SHETTY
M.B.B.S,M.D(Biochemistry)
CONSULTANT BIOCHEMIST

Dr.Shobha Emmanuel M.B.B.S,M.D(Pathology) Consultant Pathologist Dr PRASANNA B.K.P Md.Path.Pathologist

Page 13 of 13





Name : Mr. Devashish Kumar Singh

Age: 40 Y

Sex: M

Address: bangalore

Plan

: ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN

INDIA OP AGREEMENT

UHID:CINR.0000157409

OP Number:CINROPV206921 Bill No :CINR-OCR-89479

Bill No :CINR-OCR-89479
Date : 04.10.2023 09:30

ļ	Date . 04.10.202.	3 09,30
Sno	Serive Type/ServiceName	Department
1	ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - TMT - PAN INDIA - FY2324	
	URINE LUCOSE(FASTING)	
2	GAMMA GLUTAMYL TRANFERASE (GGT)	
	HbA1c, GLYCATED HEMOGLOBIN	
4	LIVER FUNCTION TEST (LFT)	
5	X-RAY CHEST PA	
6	&LUCOSE, FASTING	
7	HEMOGRAM + PERIPHERAL SMEAR	
	ENT CONSULTATION	
9	CAROTAC STRESS TEST(TMT)	
10	FITNESS BY GENERAL PHYSICIAN	
11	DIET CONSULTATION	·
	COMPLETE URINE EXAMINATION	
13	URINE GLUCOSE(POST PRANDIAL)	
14	PERIDHERAL SMEAR	
15	ECG ~ U	
16	BLOOD GROUP ABO AND RH FACTOR	
17	LIPID PROFILE	
√48	BODY MASS INDEX (BMI)	
119	OPTHALBY GENERAL PHYSICIAN - 5 NOVMON with glaves.	
20	RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
-21	UDTRASOUND - WHOLE ABDOMEN -9 2 Pm	
22	PHYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	1974
	DENTAL CONSULTATION — 1.	
· · · · · · · · · · · · · · · · · · ·	GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL)	
7		





Date

04-10-2023

Department

: GENERAL

MR NO

CINR.0000157409

Doctor

Resp: 1

Name

: Mr. Devashish Kumar Singh

Pulse: 子

Registration No

Qualification

Age/ Gender

History

40 Y / Male

Gonsultation Timing: 09:29

Height:

General Examination / Allergies

Weight:

BMI: 2

Waist Circum: 9

Temp: OR

Clinical Diagnosis & Management Plan

Follow up date:

Doctor Signature

Apollo Clinic, Indiranagar

#2012, 1st Floor, 100 Feet Road, HAL 2nd Stage, Indiranagar - 560038

Phone: (080) 2521 4614/15

Follow us 7/ApolloClinicIndia //ApolloClinics

BOOK YOUR APPOINTMENT TODAY!

Whatsapp Number: 970 100 3333

Toll Number

: 1860 500 7788

Website

: www.apolloclinic.com

04.10.2023 11:32:47am 40 yrs Indian Meds: 165 cm 68 kg

Medical History: Test Reason:

Ref. MD: Ordering MD: Technician: Test Type:

Comment:

of the it

VE recovery: 0 VE/min HR recovery: 41 bpm ST/HR slope: 0.71 µV/bpm (III) ST/HR index: 1.37 µV/bpm HR reserve used: 69 % Max. ST: -1.00 mm, 1.25 mV/s in V3; EXERCISE STAGE 3 6:59 Maximum Workload: 10.10 METS Max BP: 120/80 mmHg Max RPP: 18120 mmHg*bpm Max HR: 151 bpm 83 % of max predicted 180 bpm HR at rest: 81 BRUCE: Exercise Time 07:01

ST/HR hysteresis: 0.052 mV (V2)

QRS duration: BASELINE: 96 ms, PEAK EX: 96 ms, REC: 98 ms

Reasons for Termination: Target heart rate achieved

Resting ECG: normal. Functional Capacity: normal. HR Response to Exercise: Summary:

NORMAL HR AND BP RESPONSE Conclusion: GOOD EFFORT TOLERANCE

Normal stress test.

Chest Pain: none. Arrhythmias: none. ST Changes: none. Overall impression: appropriate. BP Response to Exercise: normal resting BP - appropriate response.

NO ANGINA AND ARRYTHMIA DURING TEST

STRESS TEST IS NEGATIVE FOR THE EXERCISE INDUCIBLE ISCHEMIA

Location: * 0 *

Phase Name

RECOVERY	EXERCISE	PRETEST	Phase Name
STAGE 3	HYPERV. STAGE 1 STAGE 2	SUPINE STANDING	Stage Name
01:01	00:22 03:00 03:00	in Stage 00:26 00:20	Time
3.40 0.00	1.00 1.70	[mph] 0.00 0.00	Speed
14.00 14.00 0.00	0.00 ·	0.00	Grade
	4.6 1.2		
133 150 91	90 121	[bpm]	H _R
120/80 120/80	120/80	[mmHg]	D U
15960 18000 10920	14520	mmHe*p	D
000	000	VE [/mim] 0	
0.10 -0.90 0.10	1.65 1.55	ST Level V3 [mm] 1.80	
		Comment	

Attending MD:

MR DEVASHISH KUMAR, SINGH Patient ID: 157409 04.10.2023 165 cm 68 kg 11:32:56am

165 cm 68 kg 40 yrs Indian

88 bpm

PRETEST SUPINE 0 00:03

BRUCE 0.0 mph 0.0 %

81 bpm

BRUCE 0.0 mph 0.0 %


APOLLO CLINIC

165 cm 68 kg 40 yrs Indian


PRETEST STANDING 00:26

APOLLO CLINIC

PRETEST HYPERV. 00:47



77



Exercise Test / Linked Medians

165 cm 68 kg 40 yrs Indian

11:36:45am

EXERCISE STAGE I 02:50

120 bpm

BRUCE 1.7 mph 10.0 %

APOLLO CLINIC

0.85 1.45 2.79 Lead
ST Level (mm)
ST Slope (mV/s)

-0.40 -0.69

0.25 1.08

2.09 1.10


0.95 1.86

*Computer Synthesized Rhythms

11:39:45am 04.10.2023 165 cm 68 kg 40 yrs Indian

STAGE 2 05:50 EXERCISE

BRUCE 2.5 mph 12.0 %



Patient ID: 157409

11:40:56am 04.10.2023

40 yrs Indian 165 cm 68 kg


150 bpm

EXERCISE STAGE 3

BRUCE 3.4 mph 14.0 %

Lead
ST Level (mm)
ST Slope (mV/s)

APOLLO CLINIC



*Computer Synthesized Rhythms

11:41:56am

165 cm 68 kg 40 yrs Indian

109 bpm

01:00 RECOVERY

BRUCE 0.0 mph 0.0 %


APOLLO CLINIC

1.25 2.52 1.10 3.31 Lead ST Level (mm) ST Slope (mV/s)

0.90 2.65 0.80 1.14 *V2 1.25 2.88 3.19 *۷5 1.15

1.44 0.30 *V3 0.85 2.78 √*∨6 1.20 1.82

-0.35 -0.22



*Computer Synthesized Rhythm>

Paient ID: 157409 0410.2023 16 11:43:56am 165 cm 68 kg 40 yrs Indian

96 bpm

RECOVERY #1 03:00

BRUCE 0.0 mph 0.0 %

Lead ST Level (mm) ST Slope (mV/s)

*V5 0.25 1.25 *V4 0.25 1.41

-0.40

-0.05 0.32 #UVF 0.25 0.97


0.50 0.59

0.60 1.14

0.65

-0.45 -1.63

-0.40 -1.10



*Computer Synthesized Rhythms



LETTER OF APPROVAL / RECOMMENDATION

To.

The Coordinator, Mediwheel (Arcofemi Healthcare Limited) Helpline number: 011- 41195959

Dear Sir / Madam,

Sub: Annual Health Checkup for the employees of Bank of Baroda

This is to inform you that the following employee wishes to avail the facility of Cashless Annual Health Checkup provided by you in terms of our agreement.

PARTICULARS	EMPLOYEE DETAILS		
NAME	MR. SINGH DEVASHISH KUMAR		
EC NO.	165409		
DESIGNATION	FOREX BACK OFFICE		
PLACE OF WORK	BANGALORE, VT, NATIONAL SHARED S		
BIRTHDATE	21-02-1983		
PROPOSED DATE OF HEALTH	26-08-2023		
CHECKUP			
BOOKING REFERENCE NO.	23S165409100067808E		

This letter of approval / recommendation is valid if submitted along with copy of the Bank of Baroda employee id card. This approval is valid from **25-08-2023** till **31-03-2024** The list of medical tests to be conducted is provided in the annexure to this letter. Please note that the said health checkup is a **cashless facility** as per our tie up arrangement. We request you to attend to the health checkup requirement of our employee and accord your top priority and best resources in this regard. The EC Number and the booking reference number as given in the above table shall be mentioned in the invoice, invariably.

We solicit your co-operation in this regard.

Yours faithfully,

Sd/-

Chief General Manager HRM Department Bank of Baroda

(Note: This is a computer generated letter. No Signature required. For any clarification, please contact Mediwheel (Arcofemi Healthcare Limited))

